Harrow acquires commercial rights for Byqlovi 0.05%

Harrow (HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for Byqlovi 0.05%. Byqlovi was recently approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects Byqlovi to be available in the fourth quarter of 2025.